---
title: "Lysergide (DT120) in Generalized anxiety disorder: Special populations"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Special populations. Topics: CYP2D6 poor metabolizers, Sex, Age range studied in the generalized anxiety disorder trials, Personal or family history of psychotic or bipolar disorder and other excluded conditions, and 3 further topics. 7 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/special-populations"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Special populations

<a id="heading-2.1.2.8"></a>

## 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

### CYP2D6 poor metabolizers

> “Individuals with no functional CYP2D6 (i.e., poor metabolizers) had longer LSD half-lives and approximately 75% higher parent drug and main metabolite 2-oxo-3-hydroxy LSD area-under-the-curve blood plasma concentrations compared with carriers of functional CYP2D6.”
> “Non-functional CYP2D6 metabolizers also exhibited greater alterations of mind and longer subjective effect durations in response to LSD compared with functional CYP2D6 metabolizers.”
> “CYP2D6 is associated with several phenotypes, ranging from poor metabolizers (PMs; 5–10% in Caucasians) to ultra-rapid metabolizers (UMs; 3–5% in Caucasians), with different underlying genotypes”
> “Geno- or phenotyping may be useful in patients who undergo LSD-assisted therapy.”
> “Based on the present findings, CYP2D6 PMs may benefit from approximately 50% lower doses than those that are used in functional CYP2D6 individuals.”

Source: [Vizeli et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8149637/)

<a id="topic-2.1.2.8-2"></a>

### Sex

> “No differences in these pharmacokinetic parameters were found between male and female subjects.”

Source: [Holze et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6595343/)

> “We found no sex differences in LSD concentrations or effects consistent with previous studies using no body weight adjustment of LSD doses”

Source: [Holze et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8027607/)

<a id="topic-2.1.2.8-3"></a>

### Age range studied in the generalized anxiety disorder trials

> “The study enrolled 214 participants aged 18 to 74 years with a primary diagnosis of GAD who had a minimum Hamilton Anxiety Rating Scale (HAM-A) total score of ≥20 at screening and baseline”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

> “The eligibility criteria included age of 18 to 74 years”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-2.1.2.8-4"></a>

### Personal or family history of psychotic or bipolar disorder and other excluded conditions

> “First degree relative with or lifetime history of a psychotic disorder or bipolar disorder”
> “Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)”
> “Any clinically significant unstable illness”

Source: [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)

> “Contraindicated medical or psychiatric conditions”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-2.1.2.8-5"></a>

### Pregnancy and contraception in the trials

> “Use of highly effective methods of contraception”
> “If dosing day is >14 days from meeting the retreatment threshold, safety laboratory assessments, drug screen, and serum pregnancy test (if applicable) must be repeated.”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

> “Eligibility was evaluated at screening and baseline, with final confirmation on dosing day via a urine drug screening, urine pregnancy test, and collection of vital signs.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-2.1.2.8-6"></a>

### Renal and hepatic impairment

> “Only 1% of the administered dose was recovered from urine unchanged within the first 24 h, 16% was eliminated as 2-oxo-3-hydroxy-LSD.”

Source: [Holze et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/37596682/)

> “Sponsors should evaluate the pharmacokinetics of a psychedelic drug in patients with impaired renal function and patients with impaired hepatic function to provide dose adjustment recommendations and inform labeling.”

Source: [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-2.1.2.8-7"></a>

### Preexisting valvulopathy or pulmonary hypertension in multiple-dose studies

> “Currently, FDA recommends that sponsors exclude subjects with preexisting valvulopathy or pulmonary hypertension from multiple-dose studies of drugs with this mechanism until this risk can be better characterized.”

Source: [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
